Boundless Bio, Inc.
Clinical trials sponsored by Boundless Bio, Inc., explained in plain language.
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug BBI-825 tested in early trial
Disease control TerminatedThis early-phase trial tested an oral drug called BBI-825 in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC